Women with new-onset HTN faced a 45% greater risk of newly self-reported fibroids and those with untreated HTN had a 19% greater risk, according to a new study.
Topline KARDIA-2 findings showed zilebesiran led to clinically and statistically significant reductions in SBP on top of either a diuretic, CCB, or ARB.